

# Usher Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/U20CE3B7697BEN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: U20CE3B7697BEN

## Abstracts

The 7 major Usher syndrome markets reached a value of US\$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1.7 Billion by 2034, exhibiting a growth rate (CAGR) of 3.61% during 2024-2034.

The Usher syndrome market has been comprehensively analyzed in IMARC's new report titled "Usher Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Usher syndrome refers to a rare genetic disorder characterized by a combination of hearing loss or deafness and progressive vision loss. This condition primarily affects the inner ear, leading to varying degrees of hearing impairment, and also involves the gradual deterioration of vision due to retinitis pigmentosa, a degenerative eye disorder. The symptoms of the ailment can differ widely among patients and can occur during infancy or adulthood. Hearing loss or deafness is often present from birth or early childhood, and it can range from mild to profound. The vision loss associated with retinitis pigmentosa typically emerges later in childhood or adolescence, causing night blindness and a narrowing field of vision, ultimately leading to tunnel vision or complete blindness over time. The diagnosis of Usher syndrome involves comprehensive medical and genetic assessments. Audiological tests can determine the extent of hearing loss, while visual field tests and retinal imaging can help to identify retinitis pigmentosa.

The escalating prevalence of mutations in genes, such as MYO7A, USH1C, and CDH23, which are integral to the proper functioning of the auditory and visual systems, is primarily driving the Usher syndrome market. In addition to this, the inflating utilization of efficient therapeutic solutions, including cochlear implants for hearing loss and retinal implants for visual impairments, is also creating a positive outlook for the market.

Moreover, the widespread adoption of audiological and ophthalmological rehabilitation techniques, since they help to improve the independence and quality of life for individuals suffering from the illness, is further bolstering the market growth. Apart from this, the growing research and development activities that are poised to uncover novel treatment modalities and medications, which can alleviate or even reverse the symptoms of Usher syndrome are acting as another significant growth-inducing factor. Additionally, the emerging popularity of antioxidant supplements, such as vitamin A and vitamin E, to slow down disease progression is also augmenting the market growth. Furthermore, the escalating application of gene therapy, since it involves delivering corrective genetic material to cells, thereby rectifying or replacing the faulty genes responsible for the disorder, is expected to drive the Usher syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Usher syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Usher syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Usher syndrome market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the Usher syndrome market  
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Usher syndrome market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current usher syndrome marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Usher syndrome market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Usher syndrome market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Usher syndrome market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Usher syndrome across the seven major markets?

What is the number of prevalent cases (2018-2034) of Usher syndrome by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Usher syndrome by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Usher syndrome across the seven major markets?

What is the size of the Usher syndrome patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Usher syndrome?

What will be the growth rate of patients across the seven major markets?

### Usher Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Usher syndrome drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the Usher syndrome market?

What are the key regulatory events related to the Usher syndrome market?

What is the structure of clinical trial landscape by status related to the Usher syndrome market?

What is the structure of clinical trial landscape by phase related to the Usher syndrome market?

What is the structure of clinical trial landscape by route of administration related to the Usher syndrome market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 USHER SYNDROME - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 USHER SYNDROME - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 USHER SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 USHER SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 USHER SYNDROME - UNMET NEEDS**

## **10 USHER SYNDROME - KEY ENDPOINTS OF TREATMENT**

## **11 USHER SYNDROME - MARKETED PRODUCTS**

- 11.1 List of Usher Syndrome Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 USHER SYNDROME - PIPELINE DRUGS**

### 12.1 List of Usher Syndrome Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 NT 501 - Neurotech Pharmaceutical

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 Ultevursen - ProQR Therapeutics

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. USHER SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. USHER SYNDROME – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 USHER SYNDROME - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Usher Syndrome - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Usher Syndrome - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

- 15.3.1 Usher Syndrome - Market Size
  - 15.3.1.1 Market Size (2018-2023)
  - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Usher Syndrome - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Usher Syndrome - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Usher Syndrome - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Usher Syndrome - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Usher Syndrome - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Usher Syndrome - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Usher Syndrome - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Usher Syndrome - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Usher Syndrome - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Usher Syndrome - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Usher Syndrome - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Usher Syndrome - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Usher Syndrome - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Usher Syndrome - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Usher Syndrome - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Usher Syndrome - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

### 15.8.3 Usher Syndrome - Access and Reimbursement Overview

## 15.9 Market Scenario - Japan

### 15.9.1 Usher Syndrome - Market Size

#### 15.9.1.1 Market Size (2018-2023)

#### 15.9.1.2 Market Forecast (2024-2034)

### 15.9.2 Usher Syndrome - Market Size by Therapies

#### 15.9.2.1 Market Size by Therapies (2018-2023)

#### 15.9.2.2 Market Forecast by Therapies (2024-2034)

### 15.9.3 Usher Syndrome - Access and Reimbursement Overview

## **16 USHER SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 USHER SYNDROME MARKET - SWOT ANALYSIS**

### 17.1 Strengths

### 17.2 Weaknesses

### 17.3 Opportunities

### 17.4 Threats

## **18 USHER SYNDROME MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Usher Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/U20CE3B7697BEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U20CE3B7697BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

